Rostaporfin (SnET2, Purlytin, REM-001), a second generation photosensitizer drug, that was developed as part of Miravant's PhotoPoint photodynamic therapy (PDT) program, for the potential treatment of wet age-related macular degeneration (AMD). It was found a red light with a wavelength of 664 nm activated the drug. It is injected into the patient, where it distributed and selectively bound to plasma lipoproteins, which were produced in high concentrations by hyperproliferating cells such as cancer cells. In January 2002, results of phase III trials indicated that rostaporfin had not met the primary efficacy endpoint for the wet form of AMD. In addition, rostaporfin has been studied in phase 2 and/or Phase 3 clinical trials in cutaneous metastatic breast cancer (CMBC). It was shown that the drug was able to reduce or eliminate a substantial number of treated CMBC tumors. On March 1, 2018, Adgero Biopharmaceuticals Holdings, Inc. announced that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation to REM-001 (rostaporfin), for the treatment of Basal Cell Carcinoma Nevus Syndrome (“BCCNS”). BCCNS is a rare but serious condition with few available therapies and many patients lack treatment options.